Elicera Therapeutics Valuation
Is ELIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ELIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ELIC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ELIC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ELIC?
Other financial metrics that can be useful for relative valuation.
| What is ELIC's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 42.46m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.1x |
| Enterprise Value/EBITDA | -0.09x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ELIC's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.2x | ||
CYXO Cyxone | 4.7x | -122.2% | SEK 22.7m |
VIVE Vivesto | 23.2x | n/a | SEK 153.6m |
LPGO Lipigon Pharmaceuticals | 2.1x | 73.1% | SEK 34.7m |
NXTCL NextCell Pharma | 6.9x | n/a | SEK 105.4m |
ELIC Elicera Therapeutics | 3.3x | -109.0% | SEK 42.5m |
Price-To-Sales vs Peers: ELIC is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (9.2x).
Price to Earnings Ratio vs Industry
How does ELIC's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Sales vs Industry: ELIC is good value based on its Price-To-Sales Ratio (3.3x) compared to the Swedish Biotechs industry average (14.2x).
Price to Sales Ratio vs Fair Ratio
What is ELIC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.3x |
| Fair PS Ratio | 0.06x |
Price-To-Sales vs Fair Ratio: ELIC is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (0.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.